Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
| Current Price | ₹1,436.60 |
|---|---|
| Market Cap | ₹24,972 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 97.6 |
| Return on Equity | 19.14% |
| 52-Week Range | ₹570.75 – ₹1,899.00 |
| Beta (1Y) | 0.07 |
| Dividend Yield | 0.10% |
| Revenue | ₹534 Cr |
|---|---|
| Net Profit | ₹85 Cr |
| EPS (Basic) | ₹5.13 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-100%
RUBICON RESEARCH LIMITED is trading at ₹1,436.60, with a market capitalisation of ₹24,972 Cr.
RUBICON RESEARCH LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
RUBICON RESEARCH LIMITED has a P/E of 97.6 and a return on equity of 19.14%.
In Q1 FY27, RUBICON RESEARCH LIMITED reported revenue of ₹534 Cr and net profit of ₹85 Cr, with basic EPS of ₹5.13 (consolidated, parsed from the company's exchange filing).